Compare Biogen Inc (BIIB) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Freeport-McMoRan Inc — how do they compare? Biogen Inc trades at $196 (market cap $29.12B), while Freeport-McMoRan Inc trades at $60.49 (market cap $87.65B). The key difference: Freeport-McMoRan Inc is far larger — about 3× Biogen Inc's market cap, and Freeport-McMoRan Inc pays a 0.98% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | FCX | |
|---|---|---|
Market Cap | $29.12B | $87.65B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $71.73 |
52-Week Low | $122.68 | $35.34 |
Enterprise Value | $31.40B | $94.31B |
Dividend Yield | — | 0.98% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
